VAERS reports by lot

GSK RSV lot 75BS5: VAERS reports

25 VAERS reports list lot 75BS5 as a GSK RSV vaccine, received between 2023-09-17 and 2024-06-17. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
25
Reports
16%
Marked serious
0
With a death outcome
7
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Injection-site / Local reaction2528%
Cardiac / Cardiovascular1618%
General / Systemic (non-local)1517%
Neurological89%
Musculoskeletal78%
Thrombotic / Hematological56%
Gastrointestinal56%
Dermatological (non-injection-site)44%
Autoimmune / Immune-mediated22%
Allergic / Anaphylactic22%
Respiratory11%

Where reports came from

U.S. state of the reporter, where given (top 11).

Texas5
Florida4
North Carolina4
New York3
Illinois2
Nevada2
Pennsylvania1
West Virginia1
California1
New Jersey1
Tennessee1

Reports by month received

2023-093
2023-105
2023-113
2023-124
2024-011
2024-021
2024-068

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.